+1,847.4%
MRVL vs GSK
+80.0%
+1,767.4%
-61.9%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 10y.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | -3.4% | -1.0% | -2.4% | -3.2% |
| 7D | +8.7% | -5.4% | +14.1% | +10.2% |
| 30D | +6.9% | -4.6% | +11.5% | +8.1% |
| 3M | -10.1% | -5.1% | -5.0% | -9.6% |
| 6M | +143.4% | -11.4% | +154.9% | +149.7% |
| YTD | +167.5% | +0.7% | +166.7% | +162.8% |
| 1Y | +239.0% | +23.0% | +215.9% | +210.8% |
| 3Y | +311.0% | +48.0% | +263.0% | +237.0% |
| 5Y | +278.0% | +48.2% | +229.8% | +202.3% |
| All | +1,847.4% | +80.0% | +1,767.4% | +1,353.3% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 10y: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
10y analysis · Full analysis span regression · 6 months rolling